International Journal of Nephrology patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography,” Nephrology Dialy- sis Transplantation, vol. 19, no. 9, pp. 2307–2312, 2004. [27] A. A. Haydar, A. Covic, H. Colhoun, M. Rubens, and D. J. A. Goldsmith, “Coronary artery calciﬁcation and aortic pulse wave velocity in chronic kidney disease patients,” Kidney International, vol. 65, no. 5, pp. 1790–1794, 2004. [28] G. M. London, “Left ventricular alterations and end-stage renal disease,” Nephrology Dialysis Transplantation, vol. 17, no. 1, pp. 29–36, 2002. [29] M. L. Gross, H. P. Meyer, H. Ziebart et al., “Calciﬁca- tion of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients,” Clinical Journal of the American Society of Nephrol- ogy, vol. 2, no. 1, pp. 121–134, 2007. [30] G. M. London, S. J. Marchais, A. P. Gue´rin, and F. Me´tivier, “Arteriosclerosis, vascular calciﬁcations and cardiovascular disease in uremia,” Current Opinion in Nephrology and Hyper- tension, vol. 14, no. 6, pp. 525–531, 2005. [31] A. Y. M. Wang, S. S. Y. Ho, M. Wang et al., “Cardiac valvular calciﬁcation as a marker of atherosclerosis and arterial calciﬁcation in end-stage renal disease,” Archives of Internal Medicine, vol. 165, no. 3, pp. 327–332, 2005. [32] G. A. Block, D. M. Spiegel, J. Ehrlich et al., “Eﬀects of seve- lamer and calcium on coronary artery calciﬁcation in patients new to hemodialysis,” Kidney International, vol. 68, no. 4, pp. 1815–1824, 2005. [33] A. P. Gue´rin, G. M. London, S. J. Marchais, and F. Metivier, “Arterial stiﬀening and vascular calciﬁcations in end-stage renal disease,” Nephrology Dialysis Transplantation, vol. 15, no. 7, pp. 1014–1021, 2000. [34] S. K. Ganesh, A. G. Stack, N. W. Levin, T. Hulbert-Shearon, and F. K. Port, “Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients,” Journal of the American Society of Nephrology, vol. 12, no. 10, pp. 2131–2138, 2001. [35] M. Noordzij, J. C. Korevaar, W. J. Bos et al., “Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2513–2520, 2006. [36] S. Jono, M. D. McKee, C. E. Murry et al., “Phosphate regula- tion of vascular smooth muscle cell calciﬁcation,” Circulation Research, vol. 87, no. 7, pp. E10–E17, 2000. [37] T. P. Stompo´ r, M. Pasowicz, W. Sułowicz et al., “Trends and dynamics of changes in calciﬁcation score over the 1- year observation period in patients on peritoneal dialysis,” American Journal of Kidney Diseases, vol. 44, no. 3, pp. 517– 528, 2004. [38] A. Y. M. Wang, J. Woo, M. M. M. Sea, M. C. Law, S. F. Lui, and P. K. T. Li, “Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?” American Journal of Kidney Diseases, vol. 43, no. 4, pp. 712–720, 2004. [39] A. Y. M. Wang, C. W. K. Lam, M. Wang, I. H. S. Chan, S. F. Lui, and J. E. Sanderson, “Is valvular calciﬁcation a part of the missing link between residual kidney function and cardiac hypertrophy in peritoneal dialysis patients?” Clinical Journal of the American Society of Nephrology, vol. 4, no. 10, pp. 1629– 1636, 2009. [40] M. Mizobuchi, J. L. Finch, D. R. Martin, and E. Slatopolsky, “Diﬀerential eﬀects of vitamin D receptor activators on vascular calciﬁcation in uremic rats,” Kidney International, vol. 72, no. 6, pp. 709–715, 2007. 7 [41] G. M. Chertow, P. Raggi, S. Chasan-Taber, J. Bommer, H. Holzer, and S. K. Burke, “Determinants of progressive vascular calciﬁcation in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 19, no. 6, pp. 1489–1496, 2004. [42] G. M. London, S. J. Marchais, A. P. Gue´rin, P. Boutouyrie, F. Me´tivier, and M. C. De Vernejoul, “Association of bone activity, calcium load, aortic stiﬀness, and calciﬁcations in ESRD,” Journal of the American Society of Nephrology, vol. 19, no. 9, pp. 1827–1835, 2008. [43] C. M. Otto, J. Kuusisto, D. D. Reichenbach, A. M. Gown, and K. D. O’Brien, “Characterization of the early lesion of ‘degen- erative’ valvular aortic stenosis: histological and immun- ohistochemical studies,” Circulation, vol. 90, no. 2, pp. 844– 853, 1994. [44] M. Olsson, J. Thyberg, and J. Nilsson, “Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 5, pp. 1218–1222, 1999. [45] A. Y. M. Wang, C. W. K. Lam, M. Wang et al., “Increased cir- culating inﬂammatory proteins predict a worse prognosis with valvular calciﬁcation in end-stage renal disease: a prospective cohort study,” American Journal of Nephrology, vol. 28, no. 4, pp. 647–653, 2008. [46] H. H. Jung, S. W. Kim, and H. Han, “Inﬂammation, mineral metabolism and progressive coronary artery calciﬁcation in patients on haemodialysis,” Nephrology Dialysis Transplanta- tion, vol. 21, no. 7, pp. 1915–1920, 2006. [47] K. Yamada, S. Fujimoto, R. Nishiura et al., “Risk factors of the progression of abdominal aortic calciﬁcation in patients on chronic haemodialysis,” Nephrology Dialysis Transplantation, vol. 22, no. 7, pp. 2032–2037, 2007. [48] M. Ketteler, P. Bongartz, R. Westenfeld et al., “Association of low fetuin-A (AHSG) concentrations in serum with cardiovas- cular mortality in patients on dialysis: a cross-sectional study,” The Lancet, vol. 361, no. 9360, pp. 827–833, 2003. [49] A. Y. M. Wang, J. Woo, C. W. K. Lam et al., “Associations of serum fetuin-A with malnutrition, inﬂammation, atheroscle- rosis and valvular calciﬁcation syndrome and outcome in peri- toneal dialysis patients,” Nephrology Dialysis Transplantation, vol. 20, no. 8, pp. 1676–1685, 2005. [50] C. Scha¨fer, A. Heiss, A. Schwarz et al., “The serum protein α2-Heremans-Schmid glycoprotein/ fetuin-A is a systemically acting inhibitor of ectopic calciﬁcation,” Journal of Clinical Investigation, vol. 112, no. 3, pp. 357–366, 2003. [51] M. M. H. Hermans, V. Brandenburg, M. Ketteler et al., “Association of serum fetuin-A levels with mortality in dialysis patients,” Kidney International, vol. 72, no. 2, pp. 202–207, 2007. [52] R. C. Shroﬀ, V. Shah, M. P. Hiorns et al., “The circulating calciﬁcation inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiﬀness and calciﬁcation in children on dialysis,” Nephrology Dialysis Transplantation, vol. 23, no. 10, pp. 3263–3271, 2008. [53] W. C. O’Neill, M. K. Sigrist, and C. W. McIntyre, “Plasma pyrophosphate and vascular calciﬁcation in chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 25, no. 1, pp. 187–191, 2010. [54] G. Luo, P. Ducy, M. D. McKee et al., “Spontaneous calciﬁcation of arteries and cartilage in mice lacking matrix GLA protien,” Nature, vol. 386, no. 6620, pp. 78–81, 1997. [55] S. Jono, Y. Ikari, C. Vermeer et al., “Matrix Gla protein is associated with coronary artery calciﬁcation as assessed by electron-beam computed tomography,” Thrombosis and Haemostasis, vol. 91, no. 4, pp. 790–794, 2004.